Shattuck Labs heads into its May 1 Q1 results with the clearest tension between a surging analyst consensus and a sharp options-market shift toward caution.
Options positioning is the standout signal. The put/call ratio has jumped to 0.13 — nearly three standard deviations above its 20-day average of 0.036 — its most defensive reading in months. That move reflects a notable shift: for most of the past six weeks, calls dominated the options market by a wide margin. The reversal into puts coincides with a rough week for the stock, which fell 8.5% to close at $7.09 after a strong 18% gain through March.
The analyst story pulls in the opposite direction. The consensus is a clean "Buy" backed by five active recommendations, and the Street is raising targets with conviction. HC Wainwright tripled its price target to $18 on April 20. Cantor Fitzgerald opened coverage at Overweight on April 27 — just days before the print. Against the current $7.09 price, the mean analyst return potential sits at roughly 59%, though the spread between the most bullish targets and Citigroup's Neutral rating at $7 flags that not all of the Street is aligned. Citigroup's hold essentially prices in no upside at current levels.
The bull case centres on SL-325, Shattuck's DR3 antagonist antibody in Phase 1 trials for inflammatory bowel disease, and on a cash position that has supported multiple funding rounds. Bears point to single-asset concentration risk — if SL-325 stumbles, there is limited pipeline backstop — and to financials that remain deep in loss territory; the EV/EBITDA ratio of -6x reflects cash burn without near-term revenue. The company's EPS surprise factor ranks in the 81st percentile historically, a sign it has consistently managed expectations well, but negative earnings variability makes the trajectory hard to model.
Institutional ownership is unusually concentrated. T. Rowe Price built the largest position, adding roughly 4 million shares as of March 31 to hold nearly 10% of the company. Nextbio Capital and Point72 also entered or materially expanded positions in recent quarters — a cluster of specialist healthcare money moving in the same direction.
The May 1 print is a test of whether Phase 1 data readouts and cash runway guidance can justify the gap between where Citigroup's cautious $7 target and HC Wainwright's $18 bull case — and whether the stock can hold its month-long gains against a backdrop of fresh options hedging.
See the live data behind this article on ORTEX.
Open STTK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
